# AMN HEALTHCARE SERVICES INC (AMN) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-14  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/amn/thesis · /memo/amn

## Financial Snapshot

---
source: coverage-next-full
ticker: AMN
step: 04
title: Financial Quality & Adversarial Sweep
generated: 2026-06-14
---

### Step 04 — Financial Quality & Adversarial Sweep: AMN Healthcare Services Inc

#### 1. Statement Quality Assessment

##### Revenue Recognition

AMN recognizes staffing revenue as services are rendered (time-and-materials for shifts/assignments). Technology/VMS revenue is recognized ratably over the contract term for subscriptions, or on a fee-per-transaction basis for marketplace placements. Revenue recognition follows ASC 606 (adopted 2018). [S1]

**Quality assessment:** CLEAN. Staffing revenue recognition is straightforward — no material cutoff or acceleration concerns. Technology revenue ratable recognition is appropriate and conservative.

**Red flags:** None identified in revenue recognition. Prior year restatements: none in public record.

##### Earnings Quality Adjustments

| Item | Amount | Notes |
|------|--------|-------|
| Goodwill impairment (FY2024) | ~$182M | Non-cash; excluded from adjusted EBITDA |
| Goodwill impairment (FY2025 est.) | ~$150M | Non-cash; excludes from adjusted earnings |
| Amortization of intangibles | ~$85M/yr | Non-cash; from acquisition accounting |
| Stock-based compensation | ~$45M/yr | Non-cash dilution; legitimate operating cost |
| Restructuring charges | ~$20-30M | FY2024-2025 workforce reductions |
| SmartSquare gain (July 2025) | +$39M | One-time gain; excludes from adjusted |

**Adjusted vs. GAAP disconnect:** GAAP net income has been negative for FY2024 and FY2025 primarily due to goodwill impairment charges. Adjusted EBITDA (~$280-320M for FY2025) gives a much more favorable picture. The gap between GAAP and adjusted is larger than typical for a staffing company — investors must understand the impairment story.

**FCF vs. GAAP earnings:** FCF has remained positive throughout the decline ($219M–$578M range over FY2020-FY2022 peak, still positive in FY2024-2025). This is the key positive quality signal: even with GAAP losses from impairment, the business generates real cash. [S2]

##### Cash Flow Quality

| Metric | FY2022 (peak) | FY2023 | FY2024 | FY2025E |
|--------|--------------|--------|--------|---------|
| Operating CF | ~$650M | ~$390M | ~$275M | ~$200M |
| CapEx | ~$72M | ~$80M | ~$60M | ~$50M |
| FCF | ~$578M | ~$310M | ~$215M | ~$150M |
| FCF Margin | ~11% | ~8.1% | ~7.2% | ~5.5% |

[S2] FCF figures from StockAnalysis.com cash flow data and XBRL. FY2025 estimated.

**Working capital dynamics:** Staffing companies carry accounts receivable (typically 45-60 days DSO). AR has declined commensurate with revenue — no signs of channel stuffing or extended collections.

**CapEx intensity:** Very low (2-3% of revenue) — confirms capital-light staffing model. Technology capex is the largest component (platform development, capitalized software). CapEx trending down with revenue.

#### 2. Balance Sheet Quality

##### Goodwill & Intangibles

| Line | FY2023 | FY2024 | FY2025E |
|------|--------|--------|---------|
| Goodwill | ~$958M | ~$756M | ~$756M |
| Intangibles, net | ~$450M | ~$350M | ~$250M |
| Total goodwill + intangibles | ~$1,408M | ~$1,106M | ~$1,006M |
| Total equity | ~$1,100M | ~$850M | ~$750M |
| Tangible book value | NEGATIVE | NEGATIVE | NEGATIVE |

[S2][S3] Goodwill and intangibles data from XBRL and StockAnalysis.com.

**Goodwill risk:** Remaining goodwill of ~$756M represents ~63% of current market cap ($1.19B). Further impairment is possible if Nurse & Allied Solutions or Technology segment cash flow projections deteriorate. The $182M FY2024 + $150M FY2025 impairment history suggests management has been slow to write down acquisition premiums. This is a red flag for acquisition quality (see Step 07). [S3]

**Negative tangible book value:** AMN has negative tangible book equity ($756M goodwill + ~$250M intangibles > total stockholders' equity). This is common in acquisition-heavy staffing/services companies but means the stock cannot be valued on book value — EV/EBITDA and FCF are the appropriate anchors.

#### 3. Debt & Liquidity Quality

##### Debt Structure

| Instrument | Amount (FY2025E) | Rate | Maturity |
|-----------|-----------------|------|---------|
| Revolving credit facility | Drawn TBD | SOFR + ~175bps | ~2027 |
| Term loan | ~$400M | SOFR + ~175bps | ~2027-2028 |
| Senior secured notes | ~$300M | Fixed 4.625% | ~2027 |
| **Total gross debt** | **~$870M** | | |
| Less: cash | ~$100M | | |
| **Net debt** | **~$770M** | | |

[S4] Estimates based on investor presentation disclosure and Fitch 'BB' stable rating (confirmed June 2026).

**Leverage trajectory:**
- FY2023: ~4.5x net leverage (peak debt from Connetics/MSDR acquisitions)
- FY2024: ~4.0x
- FY2025: ~3.3x (paid $285M of debt)
- FY2026E: ~2.5-3.0x (implied by guidance + FCF)

**Maturity wall concern:** Multiple tranches mature in 2027-2028. AMN needs to refinance ~$700M+ of debt within 2 years. With Fitch 'BB' stable, refinancing is feasible but at higher rates than the current locked-in rate (Fed funds environment). Interest expense is ~$50-55M/year. [S4]

**Covenant risk:** Credit agreement likely contains leverage-based financial covenants. If adjusted EBITDA declines further, covenant headroom may compress. Investor presentation noted focus on debt reduction as a priority — consistent with management awareness of covenant risk.

#### 4. Adversarial Research Sweep

##### 4.1 Short Seller / Critical Research

No significant short seller reports identified in public record for AMN. Short interest (as of May 2026) is moderate (~5-8% of float, estimated from consensus data). The stock has already declined ~75%+ from its 2022 peak, limiting short-side upside from existing bears.

**Critical analyst notes identified:**
- Several analysts (Hold rating, $25-26 price target vs. current $30.80) argue the stock has re-rated ahead of fundamentals given Q1 2026 strike distortion
- Bears note: Q2 2026 guidance of $620-635M implies annualized revenue of ~$2.5B — AMN at $30.80 trades at ~$1.19B market cap, or ~0.47x revenue. Bears argue this is still fair value, not cheap, given leverage and competitive erosion. [S5]
- Key bear concern: no insider buying despite 75% stock decline from peak (see proxy/insider data)

##### 4.2 Legal, Regulatory & Litigation

**No material litigation identified.** Review of 10-K risk factors:
- Standard employment law risks (wage/hour claims, discrimination)
- Healthcare staffing compliance (state licensure, Joint Commission standards)
- Immigration and visa-related risks for international nurse program
- No identified class action lawsuits, SEC investigations, or material regulatory sanctions

**FCPA/International:** Limited international operations (primarily sourcing). Low FCPA risk.

##### 4.3 Accounting Red Flags Checklist

| Flag | Status | Notes |
|------|--------|-------|
| Revenue acceleration vs. cash flow | CLEAR | FCF positive, no divergence trend |
| Channel stuffing / deferred revenue | CLEAR | Services business; not applicable |
| Goodwill impairment timing | WATCH | FY2024-2025 impairments; timing questions (why not earlier?) |
| Related-party transactions | CLEAR | No unusual RPT identified in proxy |
| Auditor changes | CLEAR | KPMG consistent; no auditor change |
| Going concern language | CLEAR | No going concern in FY2025 10-K |
| Pension/off-balance obligations | LOW | Minimal pension; operating leases disclosed per ASC 842 |
| Revenue concentration | WATCH | Kaiser 16% concentration — disclosed but material |

##### 4.4 SEC Filing Review Notes

No unusual SEC comment letters in recent years. Standard 10-K and 10-Q filings with consistent accounting policies. Segment reporting consistent year-over-year. [S1]

#### 5. Financial Quality Summary

| Dimension | Rating | Notes |
|-----------|--------|-------|
| Revenue quality | HIGH | Simple services model; clean recognition |
| Earnings quality | MEDIUM | GAAP distorted by impairment; adj EBITDA cleaner |
| Cash flow quality | HIGH | FCF positive throughout decline; real cash business |
| Balance sheet quality | MEDIUM | Negative tangible book; goodwill risk; manageable leverage |
| Accounting transparency | HIGH | No restatements; clear segmentation; consistent policies |
| Governance/audit | MEDIUM-HIGH | No red flags; elevated CEO comp vs. stock performance |
| Litigation risk | LOW | No material litigation |
| **Overall** | **MEDIUM-HIGH** | Good cash business, goodwill/leverage are the watchitems |

#### Source Index

| ID | Source | Type | Retrieved |
|----|--------|------|-----------|
| S1 | AMN 10-K FY2024/FY2025 — revenue recognition, risk factors | Filing | 2026-06-14 |
| S2 | StockAnalysis.com — cash flow, balance sheet | Web | 2026-06-14 |
| S3 | SEC XBRL — goodwill, intangibles time series | API | 2026-06-14 |
| S4 | Investor presentation 2025 — debt reduction, leverage | Web | 2026-06-14 |
| S5 | Consensus.md — analyst ratings, bear concerns | Web | 2026-06-14 |
| S6 | SEC DEF 14A — governance, auditor | Filing | 2026-06-14 |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/AMN/fundamental

## Navigation

- Overview: /stocks/amn
- Financials (this page): /stocks/amn/financials
- Thesis: /stocks/amn/thesis
- Investment Memo: /memo/amn
- Coverage universe: /stocks